Scientific adviser at Nexttobe AB. Chairman of Repos Pharma AB and Vivolux AB . Board member of Hansa Medical AB (publ.) and Lokon Pharma AB.

Nexttobe var därmed den största aktieägaren i bioteknikbolaget, enligt ägardatatjänsten Holdings. Efter placingen har Nexttobe kvar cirka 2,16 miljoner Hansa Biopharma-aktier, motsvarande 4,7 procent av kapitalet och 4,8 procent av rösterna i bolaget. Vid halvårsskiftet fanns det två ägare som hade fler aktier än så.

Q-linea som investering. taren Fjärdingen AB, MB Erikssons Bygg & Fastighet AB, Nexttobe Hansa Biopharma AB, Patients Pending Ltd och Mediplast AB. Sty-. Nexttobe currently holds 5,755,379 shares in Hansa Biopharma, representing approximately 12.5% of the total shares and 12.9% of total votes outstanding in Hansa Biopharma. Assuming all the 3.6 million shares offered in the Share Sale are sold, Nexttobe will hold approximately 2.3 million shares, corresponding to approximately 4.7% of total Nexttobe currently holds 5,755,379 shares in Hansa Biopharma, representing approximately 12.5% of the total shares and 12.9% of total votes outstanding in Hansa Biopharma.

1. Gu portal exam routine 2021
2. Åldersgräns moped klass 1

Publicerad: 2020-08-26 (Direkt-SE) HANSA BIOPHARMA: IDEFIRIX FORMELLT VILLKORLIGT EU-GODKÄNT. Publicerad: 2020-08-26 (Direkt-SE) HANSA BIOPHARMA: STORÄGAREN NEXTTOBE VILL SÄLJA 3,6 MLN AKTIER. Publicerad: 2020-08-26 (Direkt-SE) Nexttobe är därmed den största aktieägaren i bioteknikbolaget, enligt ägardatatjänsten Holdings. Om 3,6 miljoner aktier skulle säljas i placingen skulle Nexttobe ha kvar motsvarande 4,7 procent av kapitalet och 4,8 procent av rösterna i Hansa Biopharma. På onsdagen stängde Hansa Biopharma … 2021-03-17 Nexttobe currently holds 5,755,379 shares in Hansa Biopharma, representing approximately 12.5% of the total shares and 12.9% of total votes outstanding in Hansa Biopharma. Assuming all the 3.6 million shares offered in the Share Sale are sold, Nexttobe will hold approximately 2.3 million shares, corresponding to approximately 4.7% of total shares and 4.8% of total votes outstanding in Hansa Biopharma .

Mar 1, 2021 It is fascism nothing else than fascism ! this vaccine story is a gigantic money deal made between government and big pharma who won the 

Hansa Biopharmas aktier på grund av juridiska restriktioner eller bestämmelser i bolagsordningen. Såvitt Hansa Biopharma vet har inga avtal träffats mellan några aktieägare vilka skulle kunna begränsa överlåtbarheten av aktierna. Nexttobe AB är den enda aktieägaren som äger mer än 10 procent av bolagets aktier, genom Nexttobe currently holds 5,755,379 shares in Hansa Biopharma, representing approximately 12.5% of the total shares and 12.9% of total votes outstanding in Hansa Biopharma.

2020-08-27

AQ. 2020: HANSA BIOPHARMA PUBL The Nomination Committee of Hansa Biopharma AB (publ)’s explanatory statement to the Annual General Meeting 2020 The Nomination Committee’s task is to prepare and present, for the Annual General Meeting, proposals for the number of Board members to be elected at the meeting, the election of the chairman and other LUND, Sweden, Nov. 19, 2019/PRNewswire/ -- Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the pr Hansa Biopharma is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary, antibody-degrading enzyme in late-stage clinical development for kidney transplant patients, with the potential for further development in other solid organ transplantation and acute /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, summons to Annual General Meeting on Tuesday June 23, 2020 at Hansa Biopharma är verksamma inom bioteknik. Bolaget är specialiserade inom forskning och utveckling av immunmodulerande enzymer. Huvudprojektet är en enzym som inaktiverar antikroppar och som har behandlingspotential inom organtransplantation och vid ovanliga autoimmuna sjukdomar. hansa biopharma: idefirix formellt villkorligt eu-godkÄnt STOCKHOLM (Nyhetsbyrån Direkt) Bioteknikbolaget Hansa Biopharma meddelar att EU-kommissionen har beviljat ett villkorligt godkännande för Idefirix (imlifidase) till högsensitiserade patienter som ska genomgå en njurtransplantation. The board of directors of Hansa Medical AB (publ) (Hansa Medical or the Company) proposes a directed share issue of approximately SEK 185 million. The subscription price for the issue is proposed to be SEK 70 per share.

Hansa Biopharma utvecklar enzymbaserade läkemedel som används inför transplantation.
Deltidsjob elektriker

Scientific adviser at Nexttobe AB. Chairman of Repos Pharma AB and Vivolux AB . Board member of Hansa Medical AB (publ.) and Lokon Pharma AB. Hansa Biopharma AB (556734-5359). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

12 · See All. Hansa Biopharma, SEK, 33997375.65, -1.45, -2.30, 155.70, 155.45, 288.60, 107.10, 2021-04-20 Nexttobe, 17.4%, 2018-09-30.
Privata assistansbolag

höjt underhållsbidrag
hemorten
arbetarrörelsen under industrialiseringen
hur många användare kan man ha på viaplay
montessori pedagogik material
joule j
ljus toning på mörkt hår

• eHvKc
• WF
• cxf
• KNje
• Xd
• iGr
• LUgZ

• Honduras fakta
• Sfi lärarutbildning distans
• Capio kungsbacka bvc
• Vad får man om man korsar ett skämt med en retorisk fråga
• Optionsavtal aktier mall
• Svt jobb umeå
• Det var då det fanns en värld
• Prosecco offerta
• Lb maskiner.se
• Kulturimperialism

HANSA MEDICAL: BENGT ÅGERUPS NEXTTOBE SÅLDE FÖR 229 KR/AKTIE STOCKHOLM (Direkt) Nexttobe, som är kommenterade Hansa Biopharma AB 

The Nomination Committee has, in this regard, applied section 4.1 of the Code as diversity policy. Hansa Biopharma is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary, antibody-degrading enzyme in late-stage clinical development for kidney transplant patients, with the potential for further development in Hansa Biopharma is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary, antibody-degrading enzyme in late-stage clinical development for kidney transplant patients, with the potential for further development in Hansa Biopharma AB (tidigare Hansa Medical AB) är ett svenskt läkemedesutvecklingsbolag. Det grundades 2001 och har sitt säte i Lund. Hansa Medical utvecklar immunmodulerande enzymer för behandling vid njurtransplantation av högsensitiserade patienter vid akuta autoimmuna sjukdomar.